International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma (Q34450381)

2 August 2017

1 reference

title

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma (English)

1 reference

2 August 2017

0 references

Jo Caers

23

0 references

Michele Cavo

Michele Cavo

28

0 references

Efstathios Kastritis

Efstathios Kastritis

9

0 references

Hans Erik Johnsen

Hans Erik Johnsen

26

0 references

Giampaolo Merlini

Giampaolo Merlini

5

0 references

Angela Dispenzieri

Angela Dispenzieri

13

0 references

Athanasios Dimopoulos

Meletios A Dimopoulos

2

0 references

Jesús San Miguel

Jesus F San Miguel

34

0 references

Robert A Kyle

31

Robert A Kyle

1 reference

2 August 2017

17

Sagar Lonial

1 reference

2 August 2017

11

Ola Landgren

1 reference

2 August 2017

32

Kenneth C Anderson

1 reference

2 August 2017

29

Hartmut Goldschmidt

1 reference

2 August 2017

1

S Vincent Rajkumar

1 reference

2 August 2017

3

Antonio Palumbo

1 reference

2 August 2017

10

Paul Richardson

1 reference

2 August 2017

16

Sonja Zweegman

1 reference

2 August 2017

7

Shaji Kumar

1 reference

2 August 2017

20

Sundar Jagannath

1 reference

2 August 2017

Sigurdur Y Kristinsson

22

Sigurdur Y Kristinsson

1 reference

2 August 2017

María Victoria Mateos

6

María-Victoria Mateos

1 reference

2 August 2017

30

Evangelos Terpos

1 reference

2 August 2017

14

Brendan Weiss

1 reference

2 August 2017

8

Jens Hillengass

1 reference

2 August 2017

12

Bruno Paiva

1 reference

2 August 2017

19

Elena Zamagni

1 reference

2 August 2017

24

Saad Z Usmani

1 reference

2 August 2017

21

Orhan Sezer

1 reference

2 August 2017

4

Joan Blade

1 reference

2 August 2017

25

Juan José Lahuerta

1 reference

2 August 2017

33

Brian G M Durie

1 reference

2 August 2017

27

Meral Beksac

1 reference

2 August 2017

Xavier LeLeu

15

1 reference

2 August 2017

Laura Rosinol

18

1 reference

2 August 2017

26 October 2014

1 reference

Lancet Oncology Commission

2 August 2017

1 reference

2 August 2017

15

1 reference

2 August 2017

e538-48

1 reference

2 August 2017

12

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

2 August 2017

1 reference

7 January 2021

Treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

A monoclonal gammopathy precedes multiple myeloma in most patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Prevalence of monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Clinical practice. Monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Solitary plasmacytoma of bone and extramedullary plasmacytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Trends and outcomes of modern staging of solitary plasmacytoma of bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

POEMS syndrome: definitions and long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

1 reference

7 January 2021

Long-term follow-up of IgM monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Treatment for High-Risk Smoldering Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

1 reference

7 January 2021

Multiple myeloma precursor disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Smoldering multiple myeloma requiring treatment: time for a new definition?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Development of early treatment strategies for high-risk myeloma precursor disease in the future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Multiple myeloma precursor disease: current clinical dilemma and future opportunities.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Prevention of progression in monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Diagnosis of smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging "early myeloma".

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Serum test for assessment of patients with Bence Jones myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Immunoglobulin free light chains and solitary plasmacytoma of bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Risk of disease progression in asymptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Prognostic features of asymptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

The pathogenesis and diagnosis of acute kidney injury in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Review of 1027 patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

How I treat POEMS syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Monoclonal gammopathy-associated proliferative glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Neuropathy and monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Smoldering multiple myeloma: natural history and recognition of an evolving type

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970442-5

7 January 2021

10.1016/S1470-2045(14)70442-5

Identifiers

DOI

1 reference

2 August 2017

1 reference